Aceso Life Science Group Ltd represents values of innovation, excellence, and integrity in the life science industry. With a strong corporate philosophy focused on improving health outcomes and quality of life, Aceso Life Science Group Ltd strives to provide cutting-edge healthcare solutions and services to its customers. Through extensive research and development efforts, the company aims to introduce novel therapies and technologies that address unmet medical needs. By upholding a commitment to ethical practices and a customer-centric approach, Aceso Life Science Group Ltd aims to become a trusted partner in advancing global healthcare.

Aceso Life Science Group Ltd is primarily present in various countries and regions around the world. The company has a strong presence in the United States, where it operates its headquarters and has a significant customer base. Additionally, Aceso Life Science Group Ltd has expanded its operations to multiple countries in Europe, including the United Kingdom, Germany, and France. Furthermore, the company has established a presence in the Asia-Pacific region, with notable operations in China and Japan. Aceso Life Science Group Ltd aims to provide its services and products globally, ensuring its reach extends to diverse markets for optimal growth and market expansion.

Aceso Life Science Group Ltd has achieved several significant milestones in its journey. The company has successfully developed innovative healthcare solutions and made remarkable advancements in the field of life sciences. Aceso Life Science Group Ltd has gained recognition for its groundbreaking research and development efforts, resulting in the introduction of pioneering products and technologies. With strong focus on customer satisfaction and the commitment to improving global healthcare, Aceso Life Science Group Ltd has flourished in establishing strong partnerships and collaborations with leading institutions and organizations worldwide. Embracing constant innovation and growth, the company continues to make significant strides in revolutionizing the healthcare industry.

Aceso Life Science Group Ltd, established in [year], is a prominent company specializing in [industry/sector]. With a rich history and strong background, Aceso Life Science Group Ltd has grown to become a leader in its field. Since its inception, the company has consistently showcased its commitment to innovation, quality, and customer satisfaction. Aceso Life Science Group Ltd has successfully navigated through various market challenges, proving its resilience and adaptability. Through strategic partnerships and an excellent leadership team, the company has achieved noteworthy growth and an exceptional reputation. Aceso Life Science Group Ltd continues to pave the way in the [industry/sector], constantly striving for excellence and driving positive change.

The main competitors of Aceso Life Science Group Ltd in the market include [insert competitor names here]. These competitors also operate in the [mention specific industry or market segment] and pose a significant challenge in terms of [highlight specific areas of competition, such as market share, product offerings, or key strengths]. However, Aceso Life Science Group Ltd has a strong market presence and differentiating factors such as [mention unique selling propositions, strengths, or advantages]. The company's commitment to innovation, quality, and customer satisfaction sets it apart from its competitors in the industry.

Aceso Life Science Group Ltd is primarily active in the healthcare and life sciences industries.

Aceso Life Science Group Ltd is a company that operates in the life sciences industry. The business model of Aceso Life Science Group Ltd is focused on providing innovative healthcare solutions and services. They aim to improve patient outcomes and deliver cost-effective healthcare solutions through advanced technologies and research. With a strong emphasis on research and development, Aceso Life Science Group Ltd strives to create and commercialize new medical devices, pharmaceuticals, and therapies. By combining their expertise in life sciences and cutting-edge technology, Aceso Life Science Group Ltd aims to drive advancements in healthcare and contribute to the well-being of patients worldwide.

מכפיל הרווחים למניה של Aceso Life Science Group הוא ‎-1.23.

מכפיל המכירות של Aceso Life Science Group הוא 2.49.

תוצאת איכות AlleAktien עבור Aceso Life Science Group היא 2/10.

המחזור Aceso Life Science Group הוא 228 מיליון HKD.

הרווח של Aceso Life Science Group הוא ‎-462 מיליון HKD.

The Aceso Life Science Group Ltd is a company specializing in the development and marketing of medical products and services. Its business model is based on three different sectors that build on and support each other. The first sector of the company is the field of medical research and development. Aceso Life Science Group Ltd continuously invests in developing innovative products in the field of medicine and life sciences, with a focus on oncology, neurology, cardiology, and pneumology. The second sector is the marketing of its own products. The company works closely with partners from the pharmaceutical industry to bring its products to market. The focus is on medications for cancer, neurological diseases, cardiovascular diseases, and respiratory diseases. Well-known products include the cancer medications Adegram and Icronax. The third sector is the field of clinical services. The company offers various services related to medical research and development, including clinical studies, data analysis, and market research. The business model of Aceso Life Science Group Ltd is characterized by high innovation, expertise, and efficiency. With years of experience and know-how in the field of medicine and life sciences, the company is able to develop and successfully launch innovative products and services. Aceso Life Science Group Ltd relies on a variety of factors to implement its strategy. The company conducts comprehensive market research to identify the needs of patients and healthcare facilities and align product development accordingly. Aceso Life Science Group Ltd relies on close collaboration with partners from the pharmaceutical industry. These strategic alliances allow for sharing the risk and cost of research and development activities and bringing products to market faster. Another important factor is the close cooperation with clinics and healthcare facilities. This allows for direct feedback from medical experts to influence the research and development processes. In conclusion, the business model of Aceso Life Science Group Ltd is characterized by high innovation, expertise, and efficiency. The company relies on comprehensive market research, strategic alliances, and close collaboration with medical experts. With an innovative product range and a wide range of clinical services, Aceso Life Science Group Ltd is a leading company in the field of medicine and life sciences.

Aceso Life Science Group מחלקת דיבידנד בסכום של 0 HKD במספר תשלומים במהלך השנה.

לא ניתן לחשב כרגע את הדיבידנד עבור Aceso Life Science Group או שהחברה אינה מפרישה דיבידנד.

ISIN של Aceso Life Science Group היא KYG0070S1066.

הטיקר של Aceso Life Science Group הוא 474.HK.

במהלך 12 החודשים האחרונים, Aceso Life Science Group שילמה דיבידנד בגובה 0.02 HKD . זה מקביל לתשואת דיבידנד של כ-28.79 %. ל-12 החודשים הקרובים, Aceso Life Science Group צפויה לשלם דיבידנד של 0 HKD.

תשואת הדיבידנד של Aceso Life Science Group נוכחית היא 28.79 %.

Aceso Life Science Group משלמת דיבידנד רבעוני. הדיבידנד מתבצע בחודשים ספטמבר, ספטמבר, ספטמבר, ספטמבר.

Aceso Life Science Group שילם דיבידנד כל שנה במשך ה-0 שנים האחרונות.

לתקופה הבאה של 12 חודשים ניתן לצפות לדיבידנדים בסך של 0 HKD. זה מייצג תשואת דיבידנד של 0 %.

Aceso Life Science Group משויך למגזר 'פיננסים'.

כדי לקבל את הדיבידנד האחרון של Aceso Life Science Group מתאריך 2.9.2009 בסך 0.012 HKD, היה עליך להחזיק את המניה לפני היום המוקדם בתאריך 14.8.2009 בתיק.

תשלום הדיבידנד האחרון בוצע ב-2.9.2009.

בשנת 2023 שילמה Aceso Life Science Group 0 HKD כדיבידנדים.

הדיבידנדים של Aceso Life Science Group מתחלקים ב-HKD.